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Pepsin hydrolysis of wheat gluten yields a tetrapeptide, Leu-Gln-Pro-Arg (1) which exhibits potent
ACE inhibitory activity. Analogues (2-7) of this peptide have been synthesized and examined for ACE
inhibitory activity in vitro and in vivo. None of the compounds synthesized showed improved in vivo ac-
tivity. However, compound 6 has been found to be as active as captopril in in vitro assay.
Angiotensin converting enzyme (ACE) is a car-
boxydipeptidase which catalyses the hydrolysis of
human prohormone, angiotensin I to the potent
vasoconstrictor octapeptide Angiotensin W·3•
ACE has also been shown to degrade neuropep-
tides like enkephalins'" and neurotensin 7,8, etc.
whose properties include interaction with cardio-
vascular system. Development of potent inhibitors
of ACE has been considered an important area to
develop potent antihypertensive drugs. The first
potent inhibitor reported by Ondetti et aL9 was a
nonapeptide teprotide. Since then a number of
shorter peptides and their analogues have been
synthesized and as a result highly potent and oral-
ly active compounds such as Captopril 10. II , enala-
priI'2.14 and isinopril'<", etc. are available in the
market. These orally active ACE inhibitors have
rapidly established themselves in the chemother-
apy of hypertension and congestive heartfai-
lure'":". On the other hand interest in peptides re-
lated to teprotide as ACE inhibitors is also contin-
uing. A number of pentapeptides and tripeptides
related to teprotide with marked ACE inhibitory
activity have been reported'V". These peptides
are having a modified peptide bond in order to
improve metabolic stability.
Interestingly, for the last two decades all the re-
search related to the designing of ACE inhibitors
have been directed towards the design of peptides
or non-peptidic compounds related to the snake
venom peptide, teprotide. Recently, Yoshikawa et
a/.21 have reported a very interesting tetrapeptide,
Leu-Gln-Pro-Arg (1). This peptide has been
shown to exhibit potent ACE inhibitory activity.
'CDRI Communication No. 5595.
Further, this peptide is derived from an edible
protein, wheat gluten. The tetrapeptide was isolat-
ed from the pepsin digests of wheat gluten at pH
2 or trypsin and chymotrypsin digestion at pH 7.
We have examined the structure activity rela-
tionship of this tetrapeptide in view of the possib-
ility of synthesising a more potent, metabolically
stable and systemically active ACE inhibitor. Since
ACE is a relatively non-specific enzyme, the inhi-
bitory property of this tetrapeptide is also likely to
unravel some important aspects for the site and
mode of action of this peptide, possibly different
from that of teprotide.
Modifications were incorporated in order to
make analogues with different Iipophilicity, en-
hanced duration of action (half life) and good in-
teraction with the charged receptors, found on the
surface of substrate. All the modifications were
carried out keeping the overall backbone confor-
mation of the resulting analogues similar to that of
parent molecule. In the first instance, Leu at the
N-terminus was replaced with Ala and Val to ob-
tain peptides with altered Iipophilicity. The second
modification was to replace the N-terminal Leu
with o-Leu with a view to achieving resistance to
degradation with aminopeptidases. The C-terminal
Arg was replaced with Lys in two analogues. This
was done to see if the guanidine side chain of Arg
plays a significant role in its interaction with the
receptor or could be replaced by basic functional-
ity of Lys. The third amino acid residue Pro was
not altered, keeping in mind the structural require-
ment for the action of zinc containing carboxydi-
peptidase. The following analogues of 1 have been
synthesized and examined for their ACE inhibito-
ry activity in vitro and in vivo.








Synthesis of peptides. Peptides were assembled
on p-benzyloxybenzyl alcohol (Wang) resin23,24
(solid support) by manual solid phase synthesis+,
Fmoc chemistry">" was employed for the synthe-
sis of all the peptides. The first Nv-Pmoc amino
acid was loaded on the p-benzyloxybenzylalcohol
resin by symmetrical anhydride using diisopropyl-
carbodiimide (DICI)28,29and 4-dimethylaminopyri-
dine (DMAP)30,31. A consistent coupling protocol
was employed for each coupling. Subsequent NU-
Fmoc amino acids were attached on the growing
peptide chain by performing the following steps in
each cycle:
(i) Cleavage of Fmoc group was carried out us-
ing 20% piperidine in DMF-CH2CI2 (1:1) (5
min IX 1 and 20 min x t). (ii) Fmoc amino acids
were activated and coupled using DICI and I-hy-
droxybenzotriazole (HOBt) in DMF-CH2CI2 (1:1).
(iii) After each coupling (step 1) and deprotection
(step 2), the resin was washed with DMF:CH2Cl2
(1:1) (1 min x 1) and CH2CI2(1 min x 3).
Prior to deprotection, the peptide couplings
were monitored by the Kaiser's test and were al-
lowed to proceed until completion (generally with-
in 120 min). After assembly of the desired peptide
chain, washing of the peptide resin was carried out
with CH2CI2, DMF-CH2Cl2 (1:1), DMF, DMF-
CH2Cl2 (1:1), CH2CI2, MeOH-CH2CLz (1:1), Me-
OH, MeOH-CH2CI2 (1:1), CH2CI2 and ether (each
2 times for 1 min). Removal of the side chain pro-
tecting groups of the protected tetrapeptide as
well as its concomitant cleavage from the resin
was achieved using TFN5.27 containing ethanedith-
iol (EDT) and thioanisole as scavengers. The
crude peptides were purified by RP-HPLC on Wa-
ters LC system. Homogeneity of purified peptides
was further established by analytical TLC and RP-
HPLC and all the peptides were found to be
> 95% pure.
In vivo ACE inhibitory activity. In vivo ACE inhi-
bitory activity was evaluated according to the
procedure reported by Smith et aJ.33 The male
Sprague Dawley rats (150-180 g) were anaesthe-
tized with pentobarbitone sodium (50 mg/kg, ip).
Blood pressure was recorded from carotid artery
through a pressure transducer (Statham P23DC,
Gross Instruments Co" USA) on a Grass model 7
polygraph (Grass Instruments Co., USA). Exter-
nal jugular vein was cannulated for intravenous in-
jections. Following 20-30 min of stabilization peri-
od, Angiotensin I(1 ug/kg in normal saline, i.v.)
induced increase in blood pressure (BP) was re-
corded. Captopril or test compounds were admin-
istered (i.v.) slowly at a dose of 1 mg/kg and after
5 min Ang I response on BP was recorded. Inhibi-
tion of Ang I response after the administration of
captopril or test compound was calculated and the
results are summarized in Table I.
In vitro ACE inhibitory activity. Table II sum-
marizes the effect of various synthetic peptides on
ACE activity. Compounds (100 nM concentration)
were incubated for 5 min with male SID rat ser-
um (which contained ACE activity), and ACE cat-
alyzed hydrolysis of 2-furanacryloyl-L-phenyl-
alanylglycylglycine (FAPGG) in 0.05 M Tris (pH
7.5) was followed at 37°C on the spectrophotome-
ter at 340 nm?". Captopril was used as a standard
drug which inhibited the ACE activity by 100% at
100 nM concentration.
It was observed that by altering the lipophilicity
of the peptide 1 at the N-terminus did not affect
the ACE activity. However, replacement of Leu
Table l=Inhibitory effect of captopril and test compounds on
angiotensin I induced pressor response on rat blood pressure


















*3-5 experiments were done for each compound)
lable II-Effect of captopril and peptides on rat serum ACE
inhibitory activity in vitro
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with o-Leu at the N-terminus resulted in signifi-
cant inhibition of ACE in the presence of this
peptide. In peptide 5 the basic functionality at the
Cvterminus was replaced with Lys which has no
effect on ACE activity. Interestingly, replacement
of Leu with o-Leu at the N terminus and Arg with
Lys at the C-terminus, led to 100% inhibition of
ACE activity. At 30 nM concentration these pep-
tides had no effect on ACE activity except 6
which produced 60% inhibition of ACE activity.
Experimental Section
General. All the opticaUy active amino acids
used in this study were of i-configuration unless
stated otherwise. The protected amino acid deriv-
atives were purchased from Novabiochem, Swit-
zerland. The deblocking reagent was freshly pre-
pared. Homogeneity and purity of the final pep-
tides were determined by TLC on silica gel-G
plates using the solvent systems: (A) n-BuOH-
pyridine-Acfrl-l-Hjt) (15:10:3:12), (B) n-BuOH-
pyridine-AcOH-H20 (45:15:10:20).
Final peptides were detected by spraying the
TLC plates with 0.2% ninhydrin solution and
heating the plates at 100°C in a hot-air oven. Final
purification and confirmation of their homogeneity
was done by HPLC on a Waters or Applied Bio-
system instrument. The solvent system used for
the analytical HPLC was a binary gradient system:
water containing 0.1% TFA (pH 2) and acetoni-
trile as the organic modifier, and the solvent pro-
gramme involved a linear gradient of 0-35% ace-
tonitrile over 45 min at a flow rate of 1 mL/min.
A u-Bondapak CIs-column (3 x 300 mm) was
used for this purpose. Preparative (50 mg) low
pressure (100 psi) chromatographic purification
was accomplished on a Shimpak Prep-ODS co-
lumn (20 x 250 mm) using a binary gradient sys-
tem. The solvent programme involved 0-25% ace-
tonitrile over 30 min, then 25-100% acetonitrile
over 30-40 min at a flow rate of 9 mLl min.
Characterization of the final purified peptides
was done -with the help of spectroscopic methods.
IH NMR spectra were taken on a Bruker 300
MHz Avance DRX spectrometer (chemical shifts
in &, ppm downfield from TMS as internal stand-
ard). The FAB mass spectra (FAB-MS) were re-
corded on a JEOL SX-I02 mass spectrometer.
Capillary melting points were determined on a Buchi
550 melting point apparatus and are uncorrected. Optical
rotations were recorded on a Perkin-Elmer 241
automatic polarimeter.
Synthesis of analogues 1-4
Fmoc-Gln-Pro-Arg(Mtr)-Resin <0. Wang resin
(2.608 g, 2.0 m moles) was taken in a reaction
vessel and swelled in DCM under nitrogen current
for 30 min. A four-fold excess of C-terminal
amino acid, Fmoc-Arg (Mtr) (5.66 g, 8 rnmoles),
diisopropylcarbodiirnide (DICI) (0.8 mL; 4
mmoles) and 4-dimethylaminopyridine (0.244 g;
2.0 mmoles) were added to this and the resin
beads stirred for 4 hr under nitrogen current.
Loading was repeated taking two-fold excess of
Fmoc-Arg(Mtr) (2.83 g, 4 mmoles). The resin was
washed properly with DMF and DCM. The tri-
peptide was assembled on the resin by successive
addition of Fmoc-Pro (0.421 g, 1.25 mmoles) and
using DICI (0.2 mL; 1.0 mmoles) as a coupling
reagent according to the protocol mentioned earli-
er. Completion of the coupling was monitored by
the Kaiser's qualitative ninhydrin test:". After as-
sembly of the tripeptide on the resin, it was
washed properly with ether and dried over P20S
in vacuo. The peptide resin (3.05 g) was divided
into four parts and each part was further used se-
parately to get the tetrapeptide by the addition of
N-terminal Fmoc-amino acid.
Leu-Gln-Pro-Arg 1. Fmoc-Gln-Pro-Argtlvlrr)-
Resin (0.760 g, 0.5 mmoles) was taken in a reac-
tion vessel and swelled in DCM. Fmoc-Leu (0.441
g, 1.25 mmoles) was coupled to tripeptide accord-
ing to the protocol mentioned earlier. The Fmoc
group was finally removed and the peptide resin
washed successively with a series of solvents as
mentioned earlier. The peptide resin was then dri-
ed in vacuo over P20S'
The protected peptide resin (0.830 g) was treat-
ed with TFA (22.5 mL) in the presence of ethane-
dithiol (1.25 mL) and thioanisole (1.25 mL) for 90
min at room temperature. The resulting crude
peptide was purified by RP-HPLC under the con-
ditions mentioned earlier. The fractions containing
the desired compound were lyophilized. The pro-
duct was found to be pure by TLC and analytical
RP-HPLC, yield 0.165 g (65%); RrA (0.59); n, B
(0.57) m.p. 108° (d); [albS-40° (c= 0.11, DMF); K'
1.93; FAB-MS: [M +H]+ (Found) 513, [M + H]"
(Calcd) mlz 513; IH NMR (DMSO-dti) & O.~6 (rn,
6H, Leu COHS), 1.5-2.2 (bm, 13H, Leu CP"Hs, Arg
CP'YHs,Pro CP'YHS, GIn CPH\ 3.1 (bs, 2H, Arg
COHs), 3.4-4.53 (CUHs), 6.9-7.4 (s, 2H, N° HS),
7.7-8.7 (NHs).
Val-Gln-Pro-Arg 2. Fmoc-Gln-Pro-Argilvltr}
Resin (0.760 g, 0.5 mmoles) was taken in a reac-
tion vessel. The Fmoc group was removed and
Fmoc-Val (0.423 g, 1.25 mmoles) coupled to the
tripeptide on the resin. The title peptide was ob-
tained in a manner similar to that mentioned
above for peptide 1. Yield 0.166 g (67%); R, A
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(0.57); Rr B(0.54); m.p. 174-76° (d); [aliP - 38.30
(C, 01; DMF); K' 1.36; FAB-MS: [M+Hf (Found)
4.99; [M+Hf (Caled) 499; IH NMR (DMSO-d6):
o 1.0 (m, 6H, Val CYHs), 1.66-2.38 (bm, 10 H,
Arg13,y IRs, Pro C13,Y HS, GIn C13Hs), 3.15 (t, 2H,
Arg COHs), 3.5-4.8 (CaHS), 7.3-8.6 (NHs).
Ala-Gln-Pro-Arg 3.Fmoc-Gln-Pro-Arg(Mtr)-
Resin (0.760 g; 0.5 mmoles) was taken in a reac-
tion vessel. The Fmoc group was removed and
Fmoc-Ala (0.388 g; 1.25 mmoles) was coupled to
the tripeptide resin I. The title peptide was ob-
tained in a manner similar to that mentioned for
peptide 1. Yield 0.145 g (62%); Rf A (0.51); Rf B
(0.49); m.p. 180-83° (d); [alb5 - 41.60 (c, 0.11,
DMF); K' 1.28; FAB-MS: [M + Hj+l (Found) m/z
471; [M + Hl+ (Calcd)m/z 471; IH NMR (DMSO-
dn): 0 1.30 (d, 3H, Ala CIl,'YHS),1.6-2.2 (bm, lOH,
Arg CIl'YHs,Pro CIl·YHs,Gin CIlHS), 3.1 (d, 2H,
Arg CbHS), 3.4-4.5 (ca, HS), 6.8-8.62 (NHS).
o-Leu-Gln-Pro-Arg 4. Fmoc-o-Leu (0.442 g;
1.25 mmoles) was coupled to the tripeptide I
(0.760 g, 0.5 mmoles) on the solid support ac-
cording to the standard coupling protocol. The ti-
tle peptide was obtained in a manner similar to
that adopted for peptide 1. Yield 0.175 g (69%);
a, A (0.62); Rr B (0.61); m.p. 21O(d);
[alb5 - 46.6°(c 0.1; DMF); K' 1.81; FAB-MS:
[M + Hj+ (Found) 513; [M + Hj+ (Calcd) 513; IH
NMR (DMSO-d6): 0 0.83 (m, 6H, Leu Ci'HS), 1.6-
2.2 (bm, 13H, Leu CIl·'YHs,Arg CIl·'YHS),3.2-4.61
(caHS), 6.9-7.4 (s, 2H, N°HS), 7.7-8.7 (NHS).
Synthesis of analogues 5-6
Fmoc-Gln-Pro-Lys (Bocj-Resin II. Fmoc Lys
(Boc) (1.872 .g, 4 mmoles) was used for loading on
the wang resm(1.306 g; 1 mmoles) by symmetrical
anhydride method. The tripeptide II was assem-
bled on the resin in a manner similar to that men-
tioned for I. Yield 1.416 g. The peptide resin
(1.416 g) was divided into two parts to be used
further for synthesizing the compounds 5 and 6.
~eu-Gln-Pro-Lys 5. Fmoc-Gln-Pro-Lys(Boc)-
Resin (0.708 g; 0.5 mmoles) was taken in a reac-
tion vessel and swelled in DCM. Fmoc-Leu (0.440
g; 1.~5 mmoles) was coupled to the tripeptide ac-
cording to the protocol mentioned earlier. The
F~oc g!OUPwas removed and the title peptide ob-
tamed m a manner similar to that mentioned for
peptide 1. Yield 0.166 g (69%); ~ A (0.56); Rr B
(0.55); m.p. 195° (d); [a155-25.8° (c 0.11, DMF);
K' 2.01; FAB-MS: [M + Hj+ (Found) 485'
[M + Hl+ (Calcd) 485; IH NMR (DMSO-dn): 0.9
(01, 6H, Leu CI\HS), 1.30 (t, 2H, Lys CYHS), 1.59
(m, 3H, Leu CIl'YHS),1.8-1.9 (m, 4H, Lys CIl'YHS),
.2.0-2.2 (bm, 8H, Gin CJ3'YHs, Pro C13'YHs),2.8 (t, 2H.
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Lys CEHS),3.74 (t, 2H, Pro COHS),4.0-4.8 (C<'HS),
6.82, 7.35 (ds, 2H, Gin N°HS), 8.0-8.9 (NHS).
n-Leu-Gln-Pro-Lys 6. Fmoc-o-Leu (0.440 g;
1.25 mmoles) was coupled to the tripeptide loaded
resin II (0.708 g; 0.5 mmoles) according to the
standard coupling protocol. The peptide 6 was
obtained in a manner similar to that mentioned for
peptide 1. Yield 0.163 g (68%); n, A (0.56); Rr B
(0.54); m.p. 179° (d); [alb5-41.6° (c 0.10, DMF),
K' 1.98; FAB-MS: [M + Hj+ (Found) 485;
[M + Hl+ (Calcd) 485; IH NMR (DMSO-d6): 0 0.9
(m, 6H, Leu COHS),1.35 (t, 2H, Lys C'YHS)1.55(rn,
3H, Leu CIl,'YHS),1.8-1.9 (m, 4H Lys CIl,l)HS),2.0-
2.2 (bm, 8H, GIn CIl·YHs,Pro CIl'YHS),2.8 (t, 2H,
Lys CEHS), 3.72 (r, 2H, Pro COHS), 4.1-4.6 (cnHS),
6.87,7.35 (ds, 2H, Gin NbHs, 8.2-8.9 (NHS).
Synthesis of o-Leu-Asn-Pro-Arg 7. The tetra-
peptide 7 was obtained by sequential addition of
Fmoc amino acids on the wang resin (0.654 g; 0.5
mmoles) in a manner similar to that described for
the analogue 4. However, Fmoc-Asn (0.439 g,
1.25 mmoIes) was used at the dipeptide stage in
place of Fmoc-Gln, The crude peptide obtained
by the cleavage from the solid support was purifi-
ed by HPLC. Yield 0.150 g (60%); Rr A (0.56); n,
B (0.55); m.p. 192° (d); [alb5 - 46.6° (c 0.1, DMF);
K' 1.66; FAB-MS: [M + H]" (Found) 499;
[M + Hj+ (Calcd) 499; IH NMR (DMSO-c4: 0
0.88 (bs, 6H, Leu COHs, 1.5-1.75(bm, 7H, Leu
CIl,'YHs,Arg CIl'YH5)1.89-2.1 (m, 4H, Pro CIl'YHS),
3.08 (d, H, Asn CIlHS), 3.4 (r, 2H, Arg CbHS),
3.80 (t, 2H, Pro COHS), 4.1-4.9 (caHS, 7.02,7.52
(ds, 2H, Asn NYHS),7.75-8.92 (NHS).
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